Search

Aripiprazole lauroxil

Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of

Drostanolone propionate

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. … [A261496] Avelumab was first approved by the FDA on March 23, 2017.

Vamorolone

It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function … Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals.

Retifanlimab

By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed

Pancuronium

As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus

Ketamine

It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.

Lyme disease vaccine (recombinant OspA)

Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

Ustekinumab

In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.